These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1503488)

  • 41. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment.
    Kris MG; Gralla RJ; Kalman LA; Kelsen DP; Casper ES; Burke MT; Groshen S; Cibas IR; Bagin R; Heelan RT
    Cancer Treat Rep; 1985 Apr; 69(4):387-95. PubMed ID: 3888388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Radiotherapy combined with cis-diammine-dichloro platinum (II) plus vindesine in the treatment of non-small cell lung cancer: a comparison with treatment by radiation alone].
    Koga K; Minoda S; Murai N; Nishikawa K
    Gan No Rinsho; 1990 Apr; 36(5):593-7. PubMed ID: 2157906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Organo-platinum complexes as antitumor agents (review).
    Hill JM; Speer RJ
    Anticancer Res; 1982; 2(3):173-86. PubMed ID: 6751211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Development of carboplatin].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case report of pulmonary adenocarcinoma responding to (glycolato-0,0') diammineplatinum (II), a new platinum complex.
    Sasaki Y; Ohta T; Tamura T; Eguchi K; Shinkai T; Noguchi M; Saijo N
    Jpn J Clin Oncol; 1987 Sep; 17(3):285-90. PubMed ID: 3312721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxaliplatin activity in head and neck cancer cell lines.
    Espinosa M; Martinez M; Aguilar JL; Mota A; De la Garza JG; Maldonado V; Meléndez-Zajgla J
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):301-5. PubMed ID: 15619139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Chemotherapy of solid tumors. The role of cisplatin in today's chemotherapy].
    Kenis Y; Rozencweig M; Sanders C
    Rev Med Brux; 1983 Apr; 4(4):213-7. PubMed ID: 6683864
    [No Abstract]   [Full Text] [Related]  

  • 50. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
    Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of cis-platinum in solid-tumor therapy.
    Einhorn LH; Williams SD
    N Engl J Med; 1979 Feb; 300(6):289-91. PubMed ID: 366407
    [No Abstract]   [Full Text] [Related]  

  • 52. cis-Platinum ototoxicity.
    Helson L; Okonkwo E; Anton L; Cvitkovic E
    Clin Toxicol; 1978; 13(4):469-78. PubMed ID: 747905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A new cytostatic agent: cis-dischlorodiamin platinum II (DDP)].
    Gallmeier WM; Bruntsch U
    MMW Munch Med Wochenschr; 1979 May; 121(18):624-7. PubMed ID: 108586
    [No Abstract]   [Full Text] [Related]  

  • 54. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
    McKeage MJ
    Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
    van der Hulst RJ; Dreschler WA; Urbanus NA
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The importance of high-tone audiometry in monitoring for ototoxicity.
    Tange RA; Dreschler WA; van der Hulst RJ
    Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carboplatin: the clinical spectrum to date.
    Canetta R; Rozencweig M; Carter SK
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():125-36. PubMed ID: 3002623
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients.
    Merrin CE
    Cancer Treat Rep; 1979; 63(9-10):1579-84. PubMed ID: 574057
    [No Abstract]   [Full Text] [Related]  

  • 59. High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa.
    Whitehorn H; Sibanda M; Lacerda M; Spracklen T; Ramma L; Dalvie S; Ramesar R
    S Afr Med J; 2014 Apr; 104(4):288-91. PubMed ID: 25118554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.
    Hayes DM; Cvitkovic E; Golbey RB; Scheiner E; Helson L; Krakoff IH
    Cancer; 1977 Apr; 39(4):1372-81. PubMed ID: 856437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.